Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin

Diabetes, Obesity and Metabolism

Volumn 9, Issue 5, 2007, Pages 733-745

  Hermansen, K ^a   Kipnes, M ^b   Luo, E ^c   Fanurik, D ^c   Khatami, Hootan ^c   Stein, P ^c  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b Diabetes and Glandular Disease Clinic   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Combination therapy; Dipeptidyl peptidase IV; DPP IV; Glimepiride; Incretins; Metformin; MK 0431; Sitagliptin

Indexed keywords

GLIMEPIRIDE; HEMOGLOBIN A1C; METFORMIN; PIOGLITAZONE; PLACEBO; SITAGLIPTIN;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA AND VOMITING; PANCREAS ISLET CELL FUNCTION; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

EID: 34547863123     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2007.00744.x     Document Type: Article

References (23)

1. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281: 2005-2012.
2. Doar JW, Thompson ME, Wilde CE, Sewell PF. Diet and oral antidiabetic drugs and plasma sugar and insulin levels in patients with maturity-onset diabetes mellitus. Br Med J 1976; 1: 498-500.
3. Hundal RS, Krssak M, Dufour S et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 2000; 49: 2063-2069.
4. Inzucchi SE, Maggs DG, Spollett GR et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998; 338: 867-872.
5. Product Information. JANUVIA (sitagliptin). Whitehouse Station: Merck & Co., Inc. October 2006.
6. Holst JJ, Deacon CF. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes 1998; 47: 1663-1670.
7. Deacon CF, Ahren B, Holst JJ. Inhibitors of dipeptidyl peptidase IV: A novel approach for the prevention and treatment of Type 2 diabetes? Expert Opin Investig Drugs 2004; 13: 1091-1102.
8. Herman GA, Stevens C, Van Dyck K et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 2005; 78: 675-688.
9. Bergman AJ, Stevens C, Zhou Y et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: A double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther 2006; 28: 55-72.
10. Herman GA, Bergman A, Stevens C et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006; 91: 4612-4619.
11. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006; 29: 2632-2637.
12. Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006; 49: 2564-2571.
13. Rosenstock J, Brazg R, Andryuk P, Lu K, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-Blind, placebo-controlled parallel group study. Clin Ther 2006; 28: 1556-1568.
14. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled on metformin alone. Diabetes Care 2006; 29: 2638-2643.
15. Idris I, Donnelly R. Dipeptidyl peptidase-IV inhibitors: A major new class of oral antidiabetic drug. Diabetes Obes Metab 2007; 9: 153-165.
16. Del Prato S, Pulizzi N. The place of sulfonylureas in the therapy for type 2 diabetes mellitus. Metabolism 2006; 55: S20-S27.
17. Brazg R, Thomas K, Zhao PL, Xu L, Chen X, Stein PP. Effect of adding MK-0431 to on-going metformin therapy in type 2 diabetic patients who have inadequate glycemic control on metformin (abstract). Diabetes 2005; 54: A3.
18. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
19. Tura A, Pacini G, Kautzky-Willer A, Ludvik B, Prager R, Thomaseth K. Basal and dynamic proinsulin-insulin relationship to assess beta-cell function during OGTT in metabolic disorders. Am J Physiol Endocrinol Metab 2003; 285: E155-E162.
20. Katz A, Nambi SS, Mather K et al. Quantitative insulin sensitivity check index: A simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000; 85: 2402-2410.
21. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2003; 26 (Suppl. 1): S33-S50.
22. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2628-2635.
23. Roberts VL, Stewart J, Issa M, Lake B, Melis R. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: Results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2005; 27: 1535-1547.